Boehringer Ingelheim Expands Oncology Portfolio With $991 Million AimedBio Antibody-Drug Conjugate Deal

SHERIDAN, WYOMING – October 15, 2025 – Boehringer Ingelheim is continuing its high-stakes investment strategy in next-generation oncology treatments, signing a deal worth up to $991 million with South Korea’s AimedBio to license an antibody-drug conjugate (ADC) for cancer. The move underscores Boehringer’s accelerating focus on precision oncology and reinforces its growing footprint in the ADC space—one of the most competitive frontiers in cancer therapeutics.